Why is Vertex Pharmaceuticals Incorporated stock rising?
Raised FY2026 total revenue guidance to $13.1 billion-$13.2 billion, reflecting stronger first-half performance and contributions from CF, CASGEVY, and JOURNAVX.
Pending acquisition of Crinetics Pharmaceuticals is expected to close in Q3 2026, adding rare endocrine diseases as Vertex's fifth commercial pillar.
Povetacicept in IgAN has a November 30, 2026 PDUFA date, and Vertex is in final commercial launch preparation.
Two additional Medicare Part D plans will cover JOURNAVX starting July 1, 2026, expanding payer access and supporting prescription-to-revenue conversion.
FDA cleared the IND for VX-017, Vertex's Type O universal donor islet cell therapy for type 1 diabetes, with Phase I/II initiation expected in the near term.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Vertex Pharmaceuticals Incorporated and 4,900+ companies.